4-氯-6-甲基-2-(三氟甲基)喹啉 | 1701-26-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯-6-甲基-2-(三氟甲基)喹啉
• 中文别名: 2-三氟甲基-4-氯-6-甲基喹啉；4-氯-2-三氟甲基-6-甲基喹啉
• 英文名称: 4-chloro-6-methyl-2-(trifluoromethyl)quinoline
• CAS: 1701-26-4
• 化学式: C₁₁H₇ClF₃N
• 分子量: 245.631
• InChiKey: ZLSXNETUGWRDSH-UHFFFAOYSA-N

物化性质

• 熔点：
  62-65°C
• 沸点：
  258.4±35.0 °C(Predicted)
• 密度：
  1.376±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2933499090
• 安全说明：
  S26,S36
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Chloro-6-methyl-2-(trifluoromethyl)quinoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Chloro-6-methyl-2-(trifluoromethyl)quinoline
CAS number: 1701-26-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H7ClF3N
Molecular weight: 245.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-6-甲基-2-(三氟甲基)喹啉 在 2,6-二甲基吡啶 、 sodium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 过氧化氢苯甲酰 作用下， 以 四氯化碳 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.5h， 生成 N-[4-[N-(4-chloro-2-trifluoromethylquinolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoyl]-L-glutamic acid
  参考文献：
  名称：

  喹啉抗叶酸胸苷酸合酶抑制剂：C2-和C4-取代基的变异。

  摘要：

  强大的胸苷酸​​合酶（TS）抑制剂N- [4- [N-[（2-氨基-3,4-二氢-4-氧代-6-喹唑啉基）甲基] -N-prop-对双环系统的修饰2-炔基氨基]苯甲酰基] -L-谷氨酸（1，CB3717）已导致合成了一系列在C2和C4位带有多个取代基的喹啉抗叶酸酯。通常，合成途径包括将适当的N- [4-（丙-2-炔丙基氨基）苯甲酰基] -L-谷氨酸二乙酯与二取代的6-（溴甲基）喹啉偶联，然后使用弱碱将其脱保护。测试了该化合物作为部分纯化的L1210 TS的抑制剂。作为细胞毒性的量度，测试了化合物对培养物中L1210细胞生长的抑制作用。发现含有氯，氨基，在C2位的甲基取代基或在C4位的氯或溴取代基。改变2h N10取代基对酶的抑制作用与在含喹唑啉酮的叶酸中观察到的相似，表明喹啉化合物可能以与喹唑啉酮类似的方式与酶相互作用。同样，将2'-氟取代基引入几种喹啉类抗叶酸剂的苯甲酰基环中会导致TS抑

  DOI：

  10.1021/jm00093a007
• 作为产物：
  描述：

  6-甲基-2-(三氟甲基)-4-喹啉醇 在 N,N-二甲基苯胺 、 三氯氧磷 作用下， 以 甲苯 为溶剂， 反应 3.5h， 生成 4-氯-6-甲基-2-(三氟甲基)喹啉
  参考文献：
  名称：

  喹啉抗叶酸胸苷酸合酶抑制剂：C2-和C4-取代基的变异。

  摘要：

  强大的胸苷酸​​合酶（TS）抑制剂N- [4- [N-[（2-氨基-3,4-二氢-4-氧代-6-喹唑啉基）甲基] -N-prop-对双环系统的修饰2-炔基氨基]苯甲酰基] -L-谷氨酸（1，CB3717）已导致合成了一系列在C2和C4位带有多个取代基的喹啉抗叶酸酯。通常，合成途径包括将适当的N- [4-（丙-2-炔丙基氨基）苯甲酰基] -L-谷氨酸二乙酯与二取代的6-（溴甲基）喹啉偶联，然后使用弱碱将其脱保护。测试了该化合物作为部分纯化的L1210 TS的抑制剂。作为细胞毒性的量度，测试了化合物对培养物中L1210细胞生长的抑制作用。发现含有氯，氨基，在C2位的甲基取代基或在C4位的氯或溴取代基。改变2h N10取代基对酶的抑制作用与在含喹唑啉酮的叶酸中观察到的相似，表明喹啉化合物可能以与喹唑啉酮类似的方式与酶相互作用。同样，将2'-氟取代基引入几种喹啉类抗叶酸剂的苯甲酰基环中会导致TS抑

  DOI：

  10.1021/jm00093a007

文献信息

• Quinoline derivatives having anti-tumor activity
  申请人：Imperial Chemical Industries PLC

  公开号：US05112837A1

  公开（公告）日：1992-05-12

  The invention relates to a quinoline of the formula: ##STR1## wherein each of R.sup.1 and R.sup.2, which may be the same or different, is hydrogen, halogeno, hydroxy, cyano, carbamoyl, nitro or amino, alkyl, alkoxy, alkylthio, alkylamino, dialkylamino or alkanoylamino each of up to 4 carbon atoms, or substituted alkyl or alkoxy each of up to 3 carbon atoms, provided that both R.sup.1 and R.sup.2 are not hydrogen; the quinoline ring may bear further substituents; R.sup.3 is hydrogen or alkyl of up to 4 carbon atoms; R.sup.4 is hydrogen, alkyl, alkenyl or alkynyl each of up to 4 carbon atoms or substituted alkyl of up to 3 carbon atoms; Ar is phenylene, naphthylene or heterocyclene which is unsubstituted or which bears one or more substituents; R.sup.5 is such that R.sup.5 --NH.sub.2 is an amino acid; or a pharmaceutically-acceptable salt or ester thereof. The compounds possess anti-tumor activity.

  本发明涉及一种喹啉，其公式为：##STR1## 其中，R.sup.1和R.sup.2可以是相同的或不同的，为氢、卤素、羟基、氰基、碳酰胺基、硝基或氨基，为碳原子数不超过4的烷基、烷氧基、烷硫基、烷氨基、二烷氨基或烷酮氨基，或为碳原子数不超过3的取代烷基或取代烷氧基，但R.sup.1和R.sup.2均不为氢；喹啉环可带有进一步的取代基；R.sup.3为氢或碳原子数不超过4的烷基；R.sup.4为氢、碳原子数不超过4的烷基、烯基或炔基，或为碳原子数不超过3的取代烷基；Ar为二价苯基、二价萘基或杂环基，其中未取代或带有1个或多个取代基；R.sup.5满足R.sup.5 --NH.sub.2是一种氨基酸；或其药用可接受的盐或酯。这些化合物具有抗肿瘤活性。
• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HEPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003099274A1

  公开（公告）日：2003-12-04

  Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.

  丙型肝炎病毒抑制剂公开了具有以下通式：其中R1、R2、R3、R'、B、Y和X在描述中有所描述。还公开了包含该化合物的组合物以及使用该化合物抑制HCV的方法。
• Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor
  申请人：——

  公开号：US20030229119A1

  公开（公告）日：2003-12-11

  The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.

  本发明涉及通过黑素浓缩激素受体对黑素浓缩激素（MCH）效果的拮抗，对于预防或治疗进食障碍、体重增加、肥胖、生殖和性行为异常、甲状腺激素分泌、利尿和水/电解质平衡、感觉处理、记忆、睡眠、觉醒、焦虑、抑郁、癫痫发作、神经退行性疾病和精神疾病是有用的。
• [EN] MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS<br/>[FR] MODULATEURS DU RÉCEPTEUR X2 DE LA PROTÉINE G ASSOCIÉE À MAS ET PRODUITS ET PROCÉDÉS ASSOCIÉS
  申请人：ESCIENT PHARMACEUTICALS INC

  公开号：WO2022067094A1

  公开（公告）日：2022-03-31

  Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 or a MRGPR X2 ortholog dependent condition, more specifically, by contacting the MRGPR X2 or the MRGPR X2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): (I) or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R1, R2, R3, R4, R5, R6and Rxare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

  提供了一种调节MRGPR X2的方法，或者用于治疗依赖于MRGPR X2或MRGPR X2同源物的情况的方法，更具体地，通过向需要的受试者分别给予具有结构（I）的化合物的有效量来接触MRGPR X2或MRGPR X2同源物：（I）或其药用可接受的盐、异构体、水合物、溶剂合物或同位素，其中W、Z、R1、R2、R3、R4、R5、R6和Rx如本文所定义。还提供了含有这些化合物的药物组合物，以及这些化合物本身。
• Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them
  申请人：Merck Sante

  公开号：EP1752450A1

  公开（公告）日：2007-02-14

  Imidazole derivatives of formula (I): wherein R1, R2a, R2b, A, V and W are as defined in the description, as inhibitors of fructose-1,6-bisphosphatase, their preparation process and their use in the prevention or treatment of diabetes, and other diseases where the inhibition of gluconeogenesis, control of blood glucose levels, reduction in glycogen stores, or reduction in insulin levels is beneficial and diseases related to the insulin resistance syndrome.

  式(I)的咪唑衍生物，其中R1、R2a、R2b、A、V和W的定义如描述所述，作为果糖-1,6-二磷酸酶抑制剂，它们的制备过程以及它们在预防或治疗糖尿病和其他疾病中的应用，这些疾病中的葡萄糖新生抑制、血糖水平控制、糖原储量减少或胰岛素水平降低是有益的，以及与胰岛素抵抗综合症相关的疾病。